ISOLATION OF SFVS THAT REGULATE TRANSCRIPTION

Information

  • Research Project
  • 2785132
  • ApplicationId
    2785132
  • Core Project Number
    R44DK051418
  • Full Project Number
    2R44DK051418-02A1
  • Serial Number
    51418
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1995 - 29 years ago
  • Project End Date
    12/31/2000 - 24 years ago
  • Program Officer Name
    MARGOLIS, RONALD N
  • Budget Start Date
    4/15/1999 - 26 years ago
  • Budget End Date
    12/31/1999 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    2
  • Suffix
    A1
  • Award Notice Date
    4/7/1999 - 26 years ago
Organizations

ISOLATION OF SFVS THAT REGULATE TRANSCRIPTION

DESCRIPTION: (Adapted from the applicant's abstract) This Phase II SBIR application discusses the rationale and approach for further development of the SMART reagent system. Phase I developed a modified two-hybrid system in yeast for isolating single-chain antibodies (sFv's) with high affinity for desired antigens in vivo. A library of human-derived sFv's was cloned into a yeast expression vector that encodes fusion proteins linking sFv's with a constitutive transactivation domain (VP16). The goal of the initial studies was to develop this technology and isolate sFv's from this library that exhibit the appropriate antigen binding specificity and are capable of targeting antigens in vivo. To expand the utility of this novel system, the aims for phase II are: 1) To construct an optimal library vector with zeocin selection to facilitate the isolation of the sFv/VP16 plasmids and to subclone a human sFv library into the new library vector. 2) To screen the new sFv/VP16zeo expression library with a variety of new baits (including transcription factors, intracellular signaling molecules and nuclear hormone receptors). 3) To use the family of human open reading frame HORF kinases that have been cloned and expressed as baits to isolate neutralizing antibodies. PROPOSED COMMERCIAL APPLICATION: Not available

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    INVITROGEN CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    CARLSBAD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    920087313
  • Organization District
    UNITED STATES